0001193125-26-211989
SEC filingMindMed's Q1 FY2026 results reflect widening losses driven by increased R&D investment in Phase 3 trials, with net loss more than tripling year-over-year.
MindMed's operating loss widened to $59.2 million in Q1 FY2026, an 84% increase from $32.2 million in the prior year period. This was primarily driven by a significant increase in research and development expenses as the company advanced its Phase 3 clinical trials for DT120 in generalized anxiety disorder (GAD) and major depressive disorder (MDD). The Voyage trial in GAD completed its sample size re-estimation in February 2026, confirming no increase in sample size was required, while the Panorama trial in MDD continues with an adaptive design. Management expects expenses to continue increasing as development and regulatory activities progress.
Net loss more than tripled to $77.1 million, compared to $23.3 million in Q1 FY2025. The increase was partly attributable to a non-cash charge from the revaluation of warrants, which was driven by an increase in the company's stock price during the quarter. Diluted earnings per share were -$0.71, compared to -$0.35 in the prior year. The company has experienced operating losses and cash outflows since inception and will require ongoing financing to continue operations.
General and administrative expenses increased compared to the prior year, driven by higher stock-based compensation and costs associated with commercial preparedness activities. As a late-stage clinical biopharmaceutical company, MindMed continues to invest in infrastructure to support potential future product launches.
The next several months are packed with high-impact clinical milestones. Topline data from the Voyage Phase 3 trial in GAD is expected in early Q3 2026, and from the Panorama trial in late Q3 2026. In MDD, the Emerge study topline readout is anticipated in late Q2 2026, with the Ascend study expected to begin dosing in Q2 2026. Additionally, initial data from the Phase 2a trial of DT402 in autism spectrum disorder is expected later in 2026. Positive results from any of these trials could be transformative for the company, while negative data would raise significant questions about the viability of its pipeline. Management has not provided quantitative revenue guidance, as the company has no approved products and does not expect meaningful revenue until commercialization.